Actively Recruiting
Study of Dolutegravir 50 mg Once Daily Versus Twice Daily with Rifampin-based Tuberculosis Treatment in Adults with HIVTB Coinfection
Led by The HIV Netherlands Australia Thailand Research Collaboration · Updated on 2024-10-02
200
Participants Needed
10
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the best dose of dolutegravir DTG for treating people co-infected with HIV and tuberculosis TB who are also receiving rifampin RIF based TB therapy. This Stage II trial aims to understand how DTG behaves in the body when combined with RIF and to compare two dosing schedules of DTG in Thai patients newly diagnosed with pulmonary, pleural, or lymph node TB confirmed to be sensitive to RIF. The study will provide important information before moving on to a larger Stage III trial focused on safety and effectiveness.
CONDITIONS
Brief Title
Efficacy, Safety and Pharmacokinetics of DTG with RIF
Research Team
J
June Ohata, BS
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
